GDTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
CytoMed Therapeutics Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$0.85−0.03 (-3.17%)
Close on Oct 19, 2026
Ownership
Who owns CytoMed Therapeutics's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
5 buys · 0 sales
Net bought $728.80K
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Wang Shu | 883,858 | 7.66% | 13G (passive) | Feb 14, 2024 |
| 28 Consultants Ltd | 880,313 | 7.62% | 13G (passive) | Feb 17, 2025 |
| Zeng Jieming | 589,239 | 5.11% | 13G (passive) | Feb 14, 2024 |
| Choo Chee Kong | 3,003,996 | 25.17% | 13D (active) amendment | Oct 12, 2026 |
| mDR LTD | 1,307,933 | 11.33% | 13G (passive) amendment | Dec 16, 2024 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Yvonne Goh | Chief Financial Officer | 25,781 | 0.22% | May 15, 2026 |
| Yoong Ying Tan | Chief Corporate Officer | 25,781 | 0.22% | May 15, 2026 |
| Chee Kong Choo | Director, 10% owner | 2,899,746 | 24.52% | Jul 24, 2026 |
| Keng Kiat Toh | Director | 4,000 | 0.03% | May 26, 2026 |
| Mark Kei Wei Leong | Director | – | – | May 15, 2026 |
| Chak Hua Yew | Director | 2,469 | 0.02% | May 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Chee Kong Choo Director, 10% owner | Jul 20, 2026 | Buy | +100,000 | $1.50 | $150.00K | 630,324 |
| Chee Kong Choo Director, 10% owner | Jul 20, 2026 | Buy | −100,000 | $1.50 | $150.00K | 630,324 |
| Chee Kong Choo Director, 10% owner | Jul 14, 2026 | Buy | +100,000 | $1.50 | $150.00K | 530,324 |
| Chee Kong Choo Director, 10% owner | Jul 14, 2026 | Buy | −100,000 | $1.50 | $150.00K | 530,324 |
| Chee Kong Choo Director, 10% owner | May 13, 2026 | Buy | +112,000 | $1.15 | $128.80K | 430,324 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Ltd mDR 10% Stockholder | Aug 11, 2026 | 117,337 | $103.26K | Aug 11, 2026 | Share Subscription |
| LTD mDR 10% Stockholder | May 13, 2026 | 117,337 | $98.09K | May 13, 2026 | Share Subscription |
| LTD mDR 10% Stockholder | Feb 12, 2026 | 117,337 | $122.03K | Feb 12, 2026 | Share Subscription |
| Ltd mDR 10% Stockholder | Sep 22, 2025 | 54,644 | $102.73K | Sep 23, 2025 | Share Subscription |
| Ltd mDR 10% Stockholder | Jun 23, 2025 | 81,482 | $171.11K | Jun 23, 2025 | Share Subscription |
| Ltd mDR 10% Stockholder | Mar 24, 2025 | 86,410 | $229.85K | Mar 24, 2025 | Share Subscription |
| Ltd mDR 10% Stockholder | Nov 4, 2024 | 115,400 | $266.00K | Nov 5, 2024 | Share Subscription |